- Founded
- 2005
- Employees
- 30
- Total Funding
- $552.7M
Founded by Maria Rupnick in 2005.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.
Leadership at Larimar Therapeutics
The team at the top of the org chart.
Carole Ben-Maimon
President & CEO
46 reports
Michael Celano
Chief Financial Officer
7 reports
Gopi Shankar
Chief Development Officer (CDO)
10 reports
Jennifer Johansson
Vice President, Legal and Compliance
14 reports
Keith E. Lynch, Jr.
VP, CMC Technical Operations
5 reports
Octavia Kane
Human Resources Director
David Chu
Executive Director, Marketing
Mohamed Hamdani
Vice President, Biometrics And DM
1 report
Frank Nazzario
Vp, Commercial
1 report
Board
Joe Truitt
Chair
Tom Hamilton
Director
Jonathan Leff
Director
Frank E. Thomas
Director
Mark Payne
Scientific Advisor
Marni Joy Falk
Scientific Advisor
Open Jobs at Larimar Therapeutics (6)
Similar companies hiring
Top employers in Medical